Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revance Therapeutics (NQ: RVNC )

13.01 +0.54 (+4.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Revance Therapeutics

< Previous 1 2 3 4 5 Next >
Why Is Revance Therapeutics (RVNC) Stock Soaring Today?
RVNC stock is jumping 12% after the FDA approved its alternative to AbbVie's Botox. Revance's injection is supposed to last longer than Botox. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
Revance Shares Shoot Higher As FDA Cleared DAXXIFY Injection For Frown Lines
The United States Food and Drug Administration (FDA) has approved Revance Therapeutics’ (NASDAQ: RVNC) lead asset DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the temporary improvement of... 
Via Benzinga
Why Asana Is Trading Higher By 24%; Here Are 24 Stocks Moving Premarket
Gainers Asana, Inc. (NYSE: ASAN) rose 24.1% to $23.62 in pre-market trading after the company reported better-than-expected results for its second quarter and issued a strong sales guidance. 
Via Benzinga
New 483 Observations Unlikely to Impact Much Awaited Revance's Daxi Approval, Says This Analyst
Via Benzinga
Revance Therapeutics: Q2 Earnings Insights
  Revance Therapeutics (NASDAQ:RVNC) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap: Revance Therapeutics Q1 Earnings
Revance Therapeutics (NASDAQ:RVNC) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
Analyst Ratings For Revance Therapeutics
Within the last quarter, Revance Therapeutics (NASDAQ:RVNC) has observed t... 
Via Benzinga
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter. 
Via Benzinga
Revance Therapeutics: Earnings Outlook
  Revance Therapeutics (NASDAQ:RVNC) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. 
Via Benzinga
Revance Therapeutics's Return On Capital Employed Insights
Benzinga Pro data, Revance Therapeutics (NASDAQ:RVNC) reported Q1 sales of $25.26 million. Earnings fell to a loss of $64.34 million, resulting in a 1.97% decrease from last quarter. 
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Daily Biotech Pulse: WHO Endorses Pfizer's Oral COVID Therapy, Vallon Pharma Surges On Strategic Review, Novavax Starts Dosing In Adolescents COVID Booster Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million. 
Via Benzinga
Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Glabellar Lines
Revance Therapeutics, Inc. (NASDAQ: RVNC) announced acceptance of Biologics License Application (BLA) by the U.S. Food and Drug Administration (FDA) of its drug candidate DaxibotulinumtoxinA for... 
Via Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Corbus Pharmaceuticals (NASDAQ:CRBP) shares increased by 20.3% to $0.4 during Monday's pre-market session. The market value of their outstanding shares is at $49.7 million. 
Via Benzinga
Revance Therapeutics: Q4 Earnings Insights
Revance Therapeutics (NASDAQ:RVNC) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Reneo Pharmaceuticals (NASDAQ:RPHM 
Via Benzinga
The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH)... 
Via Benzinga
SmileDirect Club Stock Isn’t Making a Comeback Any Time in the Near Future
SmileDirect sells itself as a growth stock, selling orthodontic services directly through storefronts. But without growth, few are buying. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Galera Therapeutics (NASDAQ:GRTX) stock increased by 134.05% to $3.23 during Tuesday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
4 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t... 
Via Benzinga
Revance Therapeutics Inc (RVNC) Q3 2021 Earnings Call Transcript
RVNC earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Jaguar Health (NASDAQ:JAGX) shares increased by 14.64% to $2.08 during Monday's regular session. The current volume of 7.2 million shares is 300.39% of Jaguar... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.